2019-11-13
Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation
Publication
Publication
Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors
Blood , Volume 134 - Issue 1 p. 1
DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
Additional Metadata | |
---|---|
doi.org/10.1182/blood-2019-124659, hdl.handle.net/1765/121593 | |
Blood | |
de Jong, C., Meijer, E., Bakunina, K., Nur, E., Van Marwijk Kooij, M., de Groot, M., … Broers, A. (2019). Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 134(1). doi:10.1182/blood-2019-124659 |